Carta Genomics
Carta Genomics provides advanced genomic testing for IVF, utilizing a novel polygenic approach (PGT-P) with a machine learning algorithm to predict disease risk and health outcomes in embryos. They analyze the entire genome, looking at all 3 billion base pairs and combining hundreds of tests to offer couples informed choices. Carta Genomics delivers clinical-grade, easy-to-understand reports and emphasizes patient data ownership, providing secure access and transferability. Their services include PGT-A (Aneuploidy), PGT-SR (Structural), PGT-M (Monogenic), and the new PGT-P (Polygenic) for complex diseases like breast cancer and diabetes. The company is focused on improving women's health and creating healthier future generations.
Carta Genomics
Carta Genomics provides advanced genomic testing for IVF, utilizing a novel polygenic approach (PGT-P) with a machine learning algorithm to predict disease risk and health outcomes in embryos. They analyze the entire genome, looking at all 3 billion base pairs and combining hundreds of tests to offer couples informed choices. Carta Genomics delivers clinical-grade, easy-to-understand reports and emphasizes patient data ownership, providing secure access and transferability. Their services include PGT-A (Aneuploidy), PGT-SR (Structural), PGT-M (Monogenic), and the new PGT-P (Polygenic) for complex diseases like breast cancer and diabetes. The company is focused on improving women's health and creating healthier future generations.